← Back to Search

Neurotoxin

5 mL Group for Overactive Bladder (BIND Trial)

Phase 4

Recruiting

Led By Rose Khavari, MD

Research Sponsored by The Methodist Hospital Research Institute

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up prior to the procedure and at 30 days post-procedure

Awards & highlights

BIND Trial Summary

This trial studies a procedure that injects a drug into the bladder to reduce symptoms of overactive bladder. It is safe and has been shown to improve symptoms. It can be done in an office with a standard dose of 100 units.

Eligible Conditions

Overactive Bladder

BIND Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 30 days post-procedure

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~30 days post-procedure

This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 days post-procedure for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Patient discomfort related to BTX-A injection

Secondary outcome measures

Impression of clinical improvement

Overall Treatment Satisfaction

Procedural Efficacy

+1 more

BIND Trial Design

2Treatment groups

Active Control

Group I: 5 mL GroupActive Control1 Intervention

100 units BTX-A reconstituted in 5 mL normal saline, injected into the bladder in 5 separate injections of 1 mL. One injection will be at the trigone.

Group II: 10 mL GroupActive Control1 Intervention

100 units BTX-A reconstituted in 10 mL normal saline, injected into the bladder in 10 separate injections of 1 mL. One injection will be at the trigone

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

The Methodist Hospital Research InstituteLead Sponsor

275 Previous Clinical Trials

80,414 Total Patients Enrolled

Rose Khavari, MDPrincipal InvestigatorThe Methodist Hospital Research Institute

9 Previous Clinical Trials

395 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has the 5 mL Group attained Food and Drug Administration endorsement?

"We gave 5 mL Group a score of 3, which is the highest rating. This indicates that this particular treatment has been given approval and passed various stages of clinical trials."

Answered by AI

Are there any current openings in this clinical research?

"Affirmative. The details posted on clinicaltrials.gov signpost that this investigation, which was published on the 7th of July 2022, is currently enrolling individuals. A total of 131 persons must be enrolled from one medical facility."

Answered by AI

How many people is this research initiative recruiting?

"Affirmative. Clinicaltrials.gov's records demonstrate that this research is presently recruiting participants, having first been made available on July 7th 2022 and last updated a few months later in December of the same year. 131 patients are being sought from one clinical site."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Procedural Discomfort Related to Number of Intradetrusor Botox Injections

Rose Khavari, M.D. 2022. "Procedural Discomfort Related to Number of Intradetrusor Botox Injections". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05652036.